A director at Deutsche Telekom AG sold 100,000 shares at 33.800EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
For as long as Telefonica and 1&1 remain separate businesses in Germany, we are going to get ongoing press stories relating to a potential deal. Last month, it was a story relating to comments from Dommermuth, which we addressed in our note at that stage.
4Q'25 vs. 4Q'24 Results Sales: € 1.058 Bn (+1.9% vs. -1.4% BS(e) and +1.0% consensus); EBITDA: € 881.0 M (+2.1% vs. +0.1% BS(e) and +1.0% consensus); FY2025 vs. FY2024 Results Sales: € 3.995 Bn (+1.4% vs. +0.5% BS(e) and +1.1% consensus); EBITDA: € 3.317 Bn (+2.1% vs. +1.5% BS(e) and +1.8% consensus); Net Profit: € -361.0 M (€ -28.0 M in FY2024);
A director at Freenet Ag bought 18,314 shares at 27.217EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Rdos. 4T'25 vs 4T'24: Ventas: 1.058 M euros (+1,9% vs +1,4% BS(e) y +1,0% consenso); EBITDA: 881,0 M euros (+2,1% vs +0,1% BS(e) y +1,0% consenso). Rdos. 2025 vs 2024: Ventas: 3.995 M euros (+1,4% vs +1,2% BS(e) y +1,1% consenso); EBITDA: 3.317 M euros (+2,1% vs +1,5% BS(e) y +1,8% consenso); BDI: -361,0 M euros (-28,0 M euros en 2024).
Ackermans & van Haaren: Results capping already strong subsidiary reporting. DPS beat. Fagron: Acquisition of Pharmavit Europe, active in nutraceutical raw materials. Fugro: Patience please. Kendrion: Sees signs of improvement in EU economy. Proximus: 2026 dividend halved, 2028-30 targets a bit better on lower capex. Proximus: 4Q25 in line EBITDA on weaker sales, FCF up; 2026 guidance below on EBITDA. Recticel: Strong FY25 results, CEO transition seen as a negative
NEWS SUMMARY: ACCIONA, ACCIONA ENERGÍA, ACERINOX, AMADEUS, CELLNEX, COLONIAL, ELECTRICITY SECTOR, FCC, GLOBAL DOMINION, GRIFOLS, IAG, MERLIN, OHLA, REDEIA, SACYR, SOLARIA, VISCOFAN. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 4Q’25 results to be released over the coming days in Spain. Doubts continue to plague Nasdaq, but software rallies after harsh punishment European s...
Proximus is holding a CMD in Brussels today that we are attending. Ahead of that, it has put out a release with FY26, FY28 guidance, and some long-term (FY30) capex and FCF estimates too. We don’t have all the detail yet, but we outline our initial thoughts in this report, and some commentary on the Q4 results too.
Proximus reported solid 4Q25 results, with the underlying EBITDA of € 437m broadly in line with expectations (kbcse: € 433m, css: € 434m) while the FY25 organic FCF of € 130m came in slightly ahead (kbcse: € 107m, css: € 102m). Although the outlook 2026 was broadly in line, we welcome the lower capex spending of between € 1.20- € 1.25bn (kbcse: € 1.30bn, css: € 1.29bn), resulting in a better than expected FCF guidance for 2026 of up to € 100m (kbcse: € 39m, css: € 24m). By 2030, the group expect...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACCIONA, ACCIONA ENERGÍA, ACERINOX, AMADEUS, CELLNEX, COLONIAL, FCC, GLOBAL DOMINION, GRIFOLS, IAG, MERLIN, OHLA, REDEIA, S. ELÉCTRICO, SACYR, SOLARIA, VISCOFAN. EUROPA:.n/a. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. Siguen las dudas en e...
Ackermans & van Haaren ends a successful year 2025 with a net profit of 593 million euros (+29%) Dear shareholder, Dear Madam, Dear Sir, Please find attached our press release with the FY2025 Results: Outstanding results at DEME, Delen Private Bank, Bank Van Breda and SIPEF boost net profit to 592.5 million euros.Equity strengthens to 5.7 billion euros, delivering a 10.3% return on equityProposal to increase the dividend to 4.60 euros per share (+21%) Best regards Ackermans & van Haaren Attachment
Ackermans & van Haaren clôture un excellent exercice 2025 avec un bénéfice net de 593 millions d'euros (+29%) Cher actionnaire, Monsieur, Madame, Veuillez trouver ci-joint notre communiqué concernant nos résultats annuels 2025: Les excellents résultats de DEME, Delen Private Bank, la Banque Van Breda et SIPEF propulsent le bénéfice net à 592,5 millions d'eurosLes fonds propres se renforcent à 5,7 milliards d'euros, générant ainsi un rendement des fonds propres de 10,3 %.Proposition d'augmenter le dividende à 4,60 euros par action (+21%) Meilleures salutations, Ackermans & van Haare...
Ackermans & van Haaren sluit een succesvol jaar af met een nettowinst van 593 miljoen euro (+29%) Geachte aandeelhouder, Geachte mevrouw, geachte heer, Gelieve bijgevoegd ons persbericht over de jaarresultaten 2025 te vinden. Uitmuntende resultaten bij DEME, Delen Private Bank, Bank Van Breda en SIPEF stuwen de nettowinst naar 592,5 miljoen euroEigen vermogen versterkt tot 5,7 miljard euro, waardoor AvH 10,3% rendement op eigen vermogen levertVoorstel om het dividend te verhogen tot 4,60 euro per aandeel (+21%) Met vriendelijke groeten, Ackermans & van Haaren Bijlage ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.